Automation, robotics, and reducing risk in cell therapy manufacturing

CPC Biocast is a podcast focused on bioprocessing in the biopharma and cell & gene therapy industries designed to educate, discuss relevant topics with industry experts and to provide best practices. In Episode 2 hosted by Nik Ekman, Application Development Manager for CPC Biopharma, he invites Fred Parietti, Co-founder of Multiply Labs to discuss automation and robotics in cell therapy manufacturing. This episode focuses on automation in cell therapy and reducing the risk of human contamination and critical points of connection during the process. As we think about helping cell therapy manufacturers get life-changing therapies to more patients, reducing risk in the manufacturing process is critical. Introducing robotics and automation into the process and removing any potential for human error is a key part of the future.   Multiply Labs is a company with a mission to build the world's best robots, and use them to make the most advanced therapies widely available. Multiply Labs' robotic technology is the gold standard for the manufacturing of these life-saving products. Episode 2 Chapter Outline: Automation in Cell Therapy and expediting advanced therapies Mimicking the human process steps of technicians to robotics Modularity and standardization in automating cell therapy processing Addressing standardization in the process from regulatory agencies IND filings and rejections due to CMC related issues How do sterile connectors fit into automation?